Pharmacologically, a novel small molecule kinase inhibitor of ROCK1/2 that preferentially accumulated in liver tissue ameliorated insulin resistance and decreased liver injury, inflammation, and fibrosis in mice fed the FFC NASH diet. This evidence concerns the gene ROCK1 and metabolic dysfunction-associated steatohepatitis.